(Q50455699)

English

Deafness associated with the use of Bortezomib in multiple myeloma

scientific article published in January 2008

In more languages

default for all languages

No label defined

No description defined

edit

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17851876

retrieved

14 March 2018

reference URL

http://europepmc.org/abstract/MED/17851876

title

Deafness associated with the use of Bortezomib in multiple myeloma (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17851876

retrieved

14 March 2018

reference URL

http://europepmc.org/abstract/MED/17851876

1 reference

Chim CS

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17851876

retrieved

14 March 2018

reference URL

http://europepmc.org/abstract/MED/17851876

Wong LG

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17851876

retrieved

14 March 2018

reference URL

http://europepmc.org/abstract/MED/17851876

publication date

1 January 2008

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17851876

retrieved

14 March 2018

reference URL

http://europepmc.org/abstract/MED/17851876

published in

Acta Oncologica

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17851876

retrieved

14 March 2018

reference URL

http://europepmc.org/abstract/MED/17851876

volume

47

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17851876

retrieved

14 March 2018

reference URL

http://europepmc.org/abstract/MED/17851876

issue

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17851876

retrieved

14 March 2018

reference URL

http://europepmc.org/abstract/MED/17851876

page(s)

323-324

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17851876

retrieved

14 March 2018

reference URL

http://europepmc.org/abstract/MED/17851876

cites work

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1080%2F02841860701558823

retrieved

21 January 2018

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1080%2F02841860701558823

retrieved

21 January 2018

The pharmacology of ototoxic drugs

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1080%2F02841860701558823

retrieved

21 January 2018

Severe irreversible bilateral hearing loss after bortezomib (VELCADE) therapy in a multiple myeloma (MM) patient

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1080%2F02841860701558823

retrieved

21 January 2018

Identifiers

DOI

10.1080/02841860701558823

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17851876

retrieved

14 March 2018

reference URL

http://europepmc.org/abstract/MED/17851876

PubMed publication ID

17851876

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17851876

retrieved

14 March 2018

reference URL

http://europepmc.org/abstract/MED/17851876

ResearchGate publication ID

5988466

0 references

(Q50455699)

Deafness associated with the use of Bortezomib in multiple myeloma

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)